<head>
<title>Core Laboratories N.V. 8K Amendment to Credit Agreement</title>
</head>

<html>

<body>

<b><font SIZE="2">
</font><font SIZE="4">
<p ALIGN="CENTER">UNITED STATES</p>
<p ALIGN="CENTER">SECURITIES AND EXCHANGE COMMISSION</p>
</font><font SIZE="2">
<p ALIGN="CENTER">Washington, D.C. 20549</p>
</font></b><font SIZE="2">
<p ALIGN="CENTER">________________</p>
</font><b><font SIZE="5">
<p ALIGN="CENTER">FORM 8-K</p>
</font></b>
<p ALIGN="CENTER"><center>
<div align="center">
  <center>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="684">
  <tr>
    <td VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN="TOP"><font SIZE="2">
      <p>CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934</font></td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">Date of report (Date of earliest event reported):<b>
      December 20, 2005</b></font></td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
</table>
  </center>
</div>
</center><font SIZE="2">
<p>&nbsp;</p>
<p>&nbsp;</p>
</font><b><font FACE="Times" SIZE="5">
<p ALIGN="CENTER">CORE LABORATORIES N.V.</p>
</font></b><font SIZE="2">
<p ALIGN="CENTER">(Exact name of Registrant as specified in its charter)</p>
<p ALIGN="CENTER">Commission File Number 001-14273</p>
<p ALIGN="CENTER">&nbsp;</p>
</font>
<p ALIGN="CENTER"><center>
<div align="center">
  <center>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="680">
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">The Netherlands</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Not Applicable</font></b></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(State or other jurisdiction of Incorporation or
      organization)</font></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(I.R.S. Employer Identification No.)</font></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Herengracht 424</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">1017 BZ Amsterdam</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">The Netherlands</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Not Applicable</font></b></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(Address of principal executive offices)</font></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(Zip Code)</font></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
</table>
  </center>
</div>
</center><font SIZE="2">
<p ALIGN="CENTER">Registrant's telephone number, including area code: <b>(31-20)
420-3191</b></p>
<p ALIGN="CENTER">&nbsp;</p>
<p ALIGN="left"><font SIZE="2">Check the appropriate below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </font></p>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="680" style="border-left-width: 0; border-top-width: 0; border-bottom-width: 0">
  <tr>
    <td WIDTH="44" style="border-style: none; border-width: medium">
    <p align="center">___</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
    <p class="MsoNormal"><font SIZE="2">Written communications
    pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">&nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">
      <font SIZE="2">
      <p align="center">___</font></td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      <p class="MsoNormal"><font SIZE="2">Soliciting material
      pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">&nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      &nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium"><font SIZE="2">
    <p align="center">___</font></td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      <p class="MsoNormal"><font SIZE="2">Pre-commencement
      communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
      240.14d-2 (b))</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">&nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium"><font SIZE="2">
    <p align="center">___</font></td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
    <p class="MsoNormal"><font SIZE="2">Pre-commencement
    communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
    240.13e-4 (c))</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">
      &nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      &nbsp;</td>
  </tr>
</table>
<hr>
<p>&nbsp;</p>
<b>
<p>Item 1.01 Entry into Material Definitive Agreement</p>
</b>
<p><font SIZE="2">On December 20, 2005, Core Laboratories N.V.
and certain of its subsidiaries, amended its Third Amended and Restated Credit
Agreement (henceforth
referred to as the &quot;Amended Credit Agreement&quot;) with various financial
institutions which are or may become parties to the Amended Credit Agreement
(collectively, the &quot;Lenders&quot;), JPMorgan Chase Bank, N.A. as administrative agent
for the Lenders and as a letter of credit issuing bank, and Bank of America, N.A.
as syndication agent for the Lenders and as a letter of credit issuing bank. The
Amended Credit Agreement increases the aggregate borrowing commitment under the
existing credit facility from $75 million to $125 million, extends the maturity
date of the facility from March 24, 2010 to December 20, 2010 and provides for
lower borrowing costs as defined in the amended agreement.&nbsp; In addition, the
Amended Credit Agreement provides an option to increase the commitment under the
credit facility to $175 million, if certain conditions are met.</font></p>
<p><font SIZE="2">The foregoing description does not purport to
be complete and is qualified in its entirety by reference to
the Amended Credit Agreement, which is filed as Exhibit 10.35 to this Current Report on Form 8-K
and is incorporated herein by
reference. </font></p>
<p>&nbsp;</p>
<b>
<p><font SIZE="2">Item 9.01. Financial Statements, Pro Forma
Financial Information and Exhibits.</font></p>
<table class="MsoNormalTable" style="width: 468.75pt" cellSpacing="0" cellPadding="0" width="625" border="0">
  <tr>
    <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" width="4%">
    &nbsp;</td>
    <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" width="4%">
    <p style="TEXT-ALIGN: right" align="right"><font SIZE="2">(c)</font></td>
    <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" width="1%">
    &nbsp;</td>
    <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 91%; PADDING-TOP: 0in" width="91%">
    <i><font SIZE="2">Exhibits</font></i></td>
  </tr>
</table>
</b>
<p>10<font SIZE="2">.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>
<font SIZE="2">First Amendment to the Third Amended and Restated
First Amendment to the Third Amended and Restated
Credit Agreement</font></p>
<b>
<p>&nbsp;</p>
<hr>
<p ALIGN="CENTER">SIGNATURES</b></p>
<p>Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
</font>
<center>
<div align="right">
<table BORDER="0" CELLSPACING="0" WIDTH="635" cellpadding="0">
  <tr>
    <td WIDTH="47%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="48%" VALIGN="TOP" COLSPAN="5"><font SIZE="2">
      <p>Core Laboratories N.V.</font></td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP"><font SIZE="2">
      <p>Dated: December 23, 2005</font></td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP"><font SIZE="2">
      <p>By</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="TOP"><font SIZE="2">
      <p style="border-bottom-style: solid; border-bottom-width: 1">/s/ Richard L. Bergmark</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="TOP"><font SIZE="2">
      <p>Richard L. Bergmark</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="TOP"><font SIZE="2">
      <p>Chief Financial Officer</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
</table>
</div>
</center><font SIZE="2">
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<hr>
</font>
<b>
<p ALIGN="CENTER">CORE LABORATORIES N.V.<br>
EXHIBIT INDEX TO FORM 8-K</b></p>
<font SIZE="2">
<p ALIGN="left">&nbsp;</p>
<p ALIGN="left">&nbsp;</p>
<p ALIGN="left">&nbsp;</p>
</font>
<center>
<div align="left">
<table CELLSPACING="0" BORDER="0" WIDTH="570" cellpadding="0">
  <tr>
    <td WIDTH="22%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p>EXHIBIT NO.</font></b></td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p>ITEM</font></b></td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="TOP"><font SIZE="2">
      <p>10.35</font></td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="TOP"><font SIZE="2">
      <p>First Amendment to the Third Amended and Restated Credit Agreement</font></td>
  </tr>
</table>
</div>
</center>
<p ALIGN="left">&nbsp;</p>

</body>

</html>
[{"type": "8-K", "sequence": "1", "filename": "clb-8k_amendcragree.htm", "description": "8-K", "secsgml_size_bytes": 12999}]
{"company-data": {"conformed-name": "CORE LABORATORIES N V", "cik": "0001000229", "assigned-sic": "1389", "irs-number": "000000000", "state-of-incorporation": "P7", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14273", "film-number": "051284502"}, "business-address": {"street1": "1017 BZ AMSTERDAM", "street2": "HERENGRACHT 424", "city": "THE NETHERLANDS", "state": "P7", "phone": "3124203191"}, "mail-address": {"street1": "6316 WINDFERN", "city": "HOUSTON", "state": "TX", "zip": "77040"}}
Core Laboratories N.V. 8K Amendment to Credit Agreement
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
December 20, 2005
CORE LABORATORIES N.V.
(Exact name of Registrant as specified in its charter)
Commission File Number 001-14273
The Netherlands
Not Applicable
(State or other jurisdiction of Incorporation or
      organization)
(I.R.S. Employer Identification No.)
Herengracht 424
1017 BZ Amsterdam
The Netherlands
Not Applicable
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(31-20)
420-3191
Check the appropriate below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
___
Written communications
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
___
Soliciting material
      pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
___
Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2 (b))
___
Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
    240.13e-4 (c))
Item 1.01 Entry into Material Definitive Agreement
On December 20, 2005, Core Laboratories N.V.
and certain of its subsidiaries, amended its Third Amended and Restated Credit
Agreement (henceforth
referred to as the "Amended Credit Agreement") with various financial
institutions which are or may become parties to the Amended Credit Agreement
(collectively, the "Lenders"), JPMorgan Chase Bank, N.A. as administrative agent
for the Lenders and as a letter of credit issuing bank, and Bank of America, N.A.
as syndication agent for the Lenders and as a letter of credit issuing bank. The
Amended Credit Agreement increases the aggregate borrowing commitment under the
existing credit facility from $75 million to $125 million, extends the maturity
date of the facility from March 24, 2010 to December 20, 2010 and provides for
lower borrowing costs as defined in the amended agreement.  In addition, the
Amended Credit Agreement provides an option to increase the commitment under the
credit facility to $175 million, if certain conditions are met.
The foregoing description does not purport to
be complete and is qualified in its entirety by reference to
the Amended Credit Agreement, which is filed as Exhibit 10.35 to this Current Report on Form 8-K
and is incorporated herein by
reference.
Item 9.01. Financial Statements, Pro Forma
Financial Information and Exhibits.
(c)
Exhibits
10
.35
First Amendment to the Third Amended and Restated
First Amendment to the Third Amended and Restated
Credit Agreement
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Core Laboratories N.V.
Dated: December 23, 2005
By
/s/ Richard L. Bergmark
Richard L. Bergmark
Chief Financial Officer
CORE LABORATORIES N.V.
EXHIBIT INDEX TO FORM 8-K
EXHIBIT NO.
ITEM
10.35
First Amendment to the Third Amended and Restated Credit Agreement